Lilly says lupus drug dropped from pipeline failed to show efficacy
An experimental BTLA agonist that Eli Lilly cut from its pipeline for lupus late last year failed to show strong enough efficacy in a mid-stage trial, the company confirmed to Endpoints News. The...
View ArticleDeep dive on pay packages; Lilly strikes $3.2B buyout; Pfizer’s R&D head to...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
Updated: Lexeo Therapeutics' gene therapy shows potential for Friedreich's...
Lexeo Therapeutics thinks its gene therapy has the potential for accelerated approval following positive interim data from two early-stage studies, the company announced Monday. Executives say the data...
View ArticleEvofem inks women’s health deal; AusperBio brings in $37M
Plus, news about Enveric, Aries Science, LENZ, MediWound and Destiny Pharma: Evofem acquires antimicrobial: The contraceptive maker is buying Lupin’s US commercial women’s health specialty business for...
View ArticleRevolution Medicines' RAS inhibitor shows promise in early-stage pancreatic...
Revolution Medicines’ experimental drug staved off cancer progression for seven and a half months in second-line metastatic pancreatic cancer patients with a variety of cancer-driving RAS mutations....
View ArticleEMA warns patients to tell doctors about GLP-1 usage before surgery
The European Medicine Agency’s safety committee said that people taking GLP-1s should let their doctor know ahead of surgery in order to avoid respiratory complications. The committee made its...
View ArticleJ&J calls proposed class action talc suit 'meritless' as settlement vote...
Johnson & Johnson asked a federal judge on Thursday to dismiss a proposed class action talc lawsuit, calling it a “misguided effort” to derail ongoing settlement talks. The lawsuit accuses J&J,...
View ArticleClik here to view.
Facing a tepid Alzheimer’s market, Lilly looks to build ‘a sense of urgency’...
On paper, Alzheimer’s disease should be an uncomplicated market for drugmakers. There are millions of potential patients, who until recently had no real option for treatment. And yet the first drugs...
View ArticleClik here to view.
Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2...
Roche shared additional Phase 1b data for the obesity drug it acquired in the Carmot Therapeutics deal that suggest a higher dose had yet to peak at six months. An abstract, which is set to be...
View ArticleClik here to view.
Exclusive: Kins raises $7M to expand in-home and virtual physical therapy
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) As purely virtual care models become more popular, physical therapy startup Kins wants to give patients...
View ArticleClik here to view.
CordenPharma injects €900M to boost GLP-1 manufacturing in US and Europe
In its biggest investment so far, CordenPharma is earmarking €900 million ($982 million) over the next three years to expand its peptide platform capacity in the US and Europe to meet rising GLP-1...
View ArticleClik here to view.
Alzheimer's biotech Asceneuron raises $100M to see if it can compete with...
A small Swiss biotech has raised a $100 million Series C to start testing its oral small molecule for Alzheimer’s disease in a Phase 2 later this year. Asceneuron, a Merck KGaA spinout, is developing...
View ArticleVertex takes federal government to court over Casgevy fertility treatment...
Vertex sued the federal government on Monday in an effort to expand its fertility support program to certain patients taking its new gene therapy for sickle cell disease and transfusion-dependent beta...
View ArticleCatalYm raises $150M in Series D to repurpose obesity target for cancer
CatalYm has racked up $150 million in an oversubscribed Series D to advance its antibody drug that neutralizes GDF15 — a target previously explored by other drugmakers for weight loss — through Phase...
View ArticleAfter last year's ImmunoGen pact, Vertex finds another conditioning agent...
Vertex is partnering with a US and South Korean biotech to see if it can offer patients a better conditioning agent to make way for an infusion of Casgevy, the biotech’s recently approved sickle cell...
View ArticleBain-backed Cardurion raises $260M to fund ex-Imara drug, buy more cardio assets
Cardurion Pharmaceuticals is going shopping for more cardio drug candidates. The Burlington, MA-based biotech, which launched in 2017 with a Takeda partnership, has raised a $260 million Series B round...
View ArticleClik here to view.
Sionna licenses clinical-stage cystic fibrosis assets from AbbVie shortly...
Sionna Therapeutics snagged the exclusive worldwide license to three of AbbVie’s cystic fibrosis drug candidates as the biotech aims to beef up its work in the genetic condition and fill gaps not...
View ArticleScorpion raises $150M for next wave of targeted cancer therapies
Scorpion Therapeutics has a fresh $150 million to work with as it moves an experimental breast cancer drug through clinical trials in an effort to best Novartis’ targeted therapy Piqray. This latest...
View ArticleClik here to view.
A teenager faced constant seizures. Could a drug developed just for him stop...
SAN DIEGO — Connor Dalby’s shrieks filled his playroom, and the rest of the house. The teenager hushed when his mom, Kelley, asked a long-coming question: “Are you ready for the big day tomorrow?” He...
View ArticleClik here to view.
Q&A: Jefferies analyst Brian Tanquilut talks Walgreens’ retreat from primary...
Retailers have struggled immensely to gain a firm foothold in healthcare delivery. Last month, Walgreens said it’ll cut its stake in primary care chain VillageMD after closing more than 100 clinic...
View Article